PVR and cancer: Blockade of KIR2DL5 with our new blocking mAb significantly enhanced NK-mediated antitumor immunity both in vitro and in vivo, demonstrating blockade of the KIR2DL5/PVR pathway as an immunotherapy for treating human cancers.